ImageneBio reports Q2 2026 results as olevaprubart pipeline advances on schedule
The company kept its Phase 2b atopic dermatitis trial on track for fourth-quarter 2027 data and said cash on hand extends its runway into early 2028.
SEC filing
Latest
2 stories
Wednesday, August 5
Thursday, July 23
ImageneBio names Yanina Grant-Huerta as CFO, effective July 20, 2026
The company also disclosed that Chief Medical Officer Benjamin Porter-Brown will shift to a consulting role starting July 24, 2026.
SEC filing